Table 6.

Demographic, Diagnostic, Genetic, CSF Biomarker, Longitudinal, and ADNI Phase Differences Between Latent Profile Classes

Variable	Mixed MCI Class	Amnestic MCI Class	LPA-Derived Normal Class	Omnibus Wald χ2Test (df)	p-value
Demographics
Age	73.72	74.01	73.79	χ2(2)=0.165	p=0.921
	(0.72)	(0.35)	(0.55)
Education	15.77	15.82	16.25	χ2(2)=3.158	p=0.206
	(0.37)	(0.15)	(0.19)
Gender (%)	42.1% F	36.6% F	45.4% F	χ2(2)=3.015	p=0.222
	(5.6)	(2.5)	(4.0)
GDS	1.85	1.54	1.75	χ2(2)=3.690	p=0.158
	(0.16)	(0.07)	(0.11)
Diagnostic Measures
WMS-R LM II	4.123	4.733	8.031,2	χ2(2)=178.914	p<0.001
	(0.359)	(0.18)	(0.19)
CDR Sum of Boxes	2.02,3	1.581,3	1.171,2	χ2(2)=63.624	p<0.001
	(0.11)	(0.05)	(0.05)
Baseline MMSE	26.342,3	27.411,3	28.431,2	χ2(2)=105.151	p<0.001
	(0.19)	(.10)	(0.11)
FAQ	4.873	3.693	1.381,2	χ2(2)=75.677	p<0.001
	(0.54)	(0.23)	(0.20)
Genetic & CSF Biomarkers
% APOE e4-positive	61.3%3	57.8%3	34.5%1,2	χ2(2)=30.014	p<0.001
	(6.3)	(3.4)	(3.4)
% high total tau	53.1%3	42.5%3	22.6%1,2	χ2(2)=17.159	p<0.001
	(9.2)	(3.9)	(3.6)
% high p-tau181p	84.2%3	64.0%3	33.4%1,2	χ2(2)=51.233	p<0.001
	(6.4)	(4.4)	(4.3)
% low Aβ1–42	81.6%3	73.0%3	29.3%1,2	χ2(2)=72.773	p<0.001
	(6.9)	(3.6)	(4.3)
% high p-tau/Aβ ratio	80.3%3	76.2%3	34.6%1,2	χ2(2)=64.444	p<0.001
	(6.9)	(3.8)	(4.3)
Longitudinal Outcome
% progression to dementia	60.0%2,3	38.3%1,3	5.8%1,2	χ2(2)=133.050	p<0.001
	(6.7)	(2.9)	(1.8)
Months until progression	15.852,3	23.421	51.151	χ2(2)=20.338	p<0.001
	(1.58)	(1.46)	(11.25)
% reversion to normal	1.2%3	0.6%3	11.2%1,2	χ2(2)=21.037	p<0.001
	(1.2)	(0.6)	(2.1)
Months until reversion	10.32	18.11	21.45	χ2(2)=8.619	p=0.013
	(1.71)	(4.29)	(3.69)
% stable MCI	38.8%2,3	61.1%1,3	83.0%1,2	χ2(2)=65.159	p<0.001
	(6.7)	(2.8)	(2.6)
Amount of total follow-up (in months)	27.74	29.23	28.02	χ2(2)=0.403	p=0.818
	(2.37)	(1.23)	(1.79)
Phase
% from ADNI1	64.3%3	53.7%3	27.4%1,2	χ2(2)=51.420	p<0.001
	(5.2)	(2.8)	(3.2)
% from ADNIGO	0.0%2,3	9.9%1,3	28.5%1,2	χ2(2)=125.303	p<0.001
	(0.0)	(1.8)	(3.1)
% from ADNI2	35.7%	36.4%	44.1%	χ2(2)=3.915	p=0.141
	(5.2)	(2.5)	(3.4)

Data summarized as mean or percent of class and (standard error) unless otherwise noted. Numbered superscripts denote significant Wald χ² test post-hoc differences at p<0.005 between each class and the class number indicated (1=Mixed MCI Class, 2=Amnestic MCI Class, 3=LPA-Derived Normal Class)

Abbreviations: MCI = Mild Cognitive Impairment; LPA = Latent Profile Analysis; χ² = chi-square; df= degrees of freedom; GDS = Geriatric Depression Scale; WMS-R LM II = Weschler Memory Scale-Revised Logical Memory II subtest; CDR = Clinical Demetia Rating Scale; MMSE = Mini-Mental State Examination; FAQ = Functional Activities Questionnaire; CSF = Cerebrospinal Fluid; APOE = Apolipoprotein; RCI = Reliable Change Index; ADNI1 = Alzheimer’s Disease Neuroimaging Initiative Phase 1; ADNIGO = Alzheimer’s Disease Neuroimaging Initiative Phase GO; ADNI2 = Alzheimer’s Disease Neuroimaging Initiative Phase